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Abstract
Previous studies showed that complement activation is associated with poor functional outcome after aneurysmal subarachnoid
hemorrhage (SAH).We investigated whether complement activation is underlying brain injury after aneurysmal SAH (n = 7) and
if it is an appropriate treatment target. We investigated complement expression in brain tissue of aneurysmal SAH patients (n =
930) and studied the role of common genetic variants in C3 and C5 genes in outcome. We analyzed plasma levels (n = 229) to
identify the functionality of a single nucleotide polymorphism (SNP) associated with outcome. The time course of C5a levels was
measured in plasma (n = 31) and CSF (n = 10). In an SAH mouse model, we studied the extent of microglia activation and cell
death in wild-type mice, mice lacking the C5a receptor, and in mice treated with C5-specific antibodies (n = 15 per group). Brain
sections from aneurysmal SAH patients showed increased presence of complement components C1q and C3/C3b/iC3B com-
pared to controls. The complement component 5 (C5) SNP correlated with C5a plasma levels and poor disease outcome. Serial
measurements in CSF revealed that C5a was > 1400-fold increased 1 day after aneurysmal SAH and then gradually decreased.
C5a in plasma was 2-fold increased at days 3–10 after aneurysmal SAH. In the SAH mouse model, we observed a ≈ 40%
reduction in both microglia activation and cell death in mice lacking the C5a receptor, and in mice treated with C5-specific
antibodies. These data show that C5 contributes to brain injury after experimental SAH, and support further study of C5-specific
antibodies as novel treatment option to reduce brain injury and improve prognosis after aneurysmal SAH.
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Introduction
Aneurysmal SAH is a devastating subtype of stroke, caused
by rupture of an aneurysm of an intracranial artery in the
subarachnoid space. Although the prognosis after aneurysmal
SAH has improved over the last decades, 90-day case fatality
is still around 30% in hospital-based studies [1]. The most
important determinant of poor functional outcome after aneu-
rysmal SAH is early brain injury directly related to the initial
bleeding [1, 2]. Other major determinants of poor functional
outcome are rebleeding of the aneurysm and delayed cerebral
ischemia, which may occur 4–14 days after the initial hemor-
rhage [1, 3]. No treatment exists for early brain injury, while
the effect of calcium antagonist nimodipine in preventing de-
layed cerebral ischemia is only modest [4]. Therefore, new
treatment options are needed to reduce brain injury after SAH.
Poor functional outcome after SAH can partially be pre-
dicted using models that include factors such as age, World
Federation of Neurological Surgeons (WFNS) scale at admis-
sion, and premorbid history of hypertension [5]. However,
these models do not take into account the inflammatory re-
sponse after SAH, which is considered to play a key role in the
pathogenesis of early brain injury and delayed cerebral ische-
mia after aneurysmal SAH [6, 7]. The inflammatory response
after SAH is independently associated with poor clinical con-
dition on admission, delayed cerebral ischemia, disability, and
death [6, 8, 9]. The inflammatory response in the brain is
reflected by the activation of microglia and astrocytes [10].
The complement system may be a major component of this
acute injury induced neuroinflammation after aneurysmal
SAH. The classical pathway of the complement system is
initiated by C1q, which then activates a cascade of other sol-
uble or membrane bound proteins. Activation of the comple-
ment system leads to the cleavage of C5, resulting in C5a and
the lytic C5b-9 membrane attack complex. Anaphylatoxins
C3a and C5a are important proinflammatory mediators and
have the potential to produce vasoconstriction and activate
coagulation by aggregation of platelets and regulation of tis-
sue factor activity [11–15]. All these processes occur after
aneurysmal SAH and are associated with early brain injury
and delayed cerebral ischemia [16–21]. Plasma levels of
mannose-binding lectin, C3a, and C5a early after SAH corre-
late with outcome at discharge [22, 23]. Despite the observed
associations between complement activation and measures of
brain injury after SAH, it remains unclear if these are causal
relationships. If so, this would represent an appealing target to
decrease brain injury and improve prognosis after SAH.
We investigated the role of complement activation after
SAH. In an autopsy study, we examined local complement
expression in brains of patients who died from aneurysmal
SAH.We evaluated the association between common comple-
ment component polymorphisms and functional outcome and
delayed cerebral ischemia, and elucidated the time-course of
complement activation in CSF and plasma after SAH using
serial measurements. We then confirmed our results in a SAH
mouse model and studied whether treatment with a C5-
specific monoclonal antibody affects brain injury after SAH.
Methods
Autopsy Study
We used autopsy material from seven SAH patients (two
males, five females, median age 56 years (range 34–77 years))
who died within 11 days after aneurysmal SAH. All patients
had delayed cerebral ischemia [3]. We isolated cortical areas
with both white and gray matter. From autopsy material from
five control patients (three males, two females, median age
72 years (range 52–75 years)) who died from non-
neurological causes (myocardial infarction: n = 3; heart fail-
ure: n = 1; pulmonary embolism: n = 1), we isolated corre-
sponding areas. Sections were stained with hematoxylin and
eosin to distinguish infarcted from non-infarcted areas. For
analysis, only non-infarcted areas were used. Complement
component C1q acts as the initiating molecule in the classical
pathway of the complement cascade, whereas C3b and iC3b
are biologically active fragments of C3, a central molecule in
the complement system. Deposition of C3/C3b/iC3b in the
tissue indicates that the complement pathway reached a pro-
inflammatory state [24]. We performed immunohistochemis-
try to investigate the presence of C1q (polyclonal rabbit, anti-
human C1q complement, #F0254, DAKO, 1:200) and C3/
C3b/iC3b (polyclonal rabbit, anti-human C3c complement,
#F0201, DAKO, 1:100). We were unable to evaluate the pres-
ence of C5a or C5b-9 (Membrane Attack Complex), as these
antibodies do not work on the paraffin-embedded postmortem
material. The immunohistochemistry of C1q and C3/C3b/
iC3b on human brain sections resulted in heterogenous stain-
ing patterns, as shown in highmagnification (× 100) images in
Supplementary Fig. 1. Optical density measurements were
used for quantitative assessments. Images were analyzed with
FIJI software (ImageJ 2.0.0). After manually selecting the
entire non-infarcted area per brain slide, selections were auto-
matically quantified, expressed as a mean total of -log trans-
formed grayscales, to calculate a mean per patient. The inves-
tigators who analyzed the immunohistochemistry images
were blinded to the experimental group.
Genotyping Study
The cohort of the genetic study consisted of 930 patients who
were admitted between 1983 and 2011 to the University
Medical Center Utrecht, the Netherlands, which is a tertiary
referral center for patients with SAH (Table 1). We used the
University Medical Center Utrecht Subarachnoid
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Hemorrhage database, which is a prospectively collected da-
tabase of consecutive patients with confirmed SAH, to collect
the following variables: age, sex, clinical condition on admis-
sion according to the WFNS grading scale [25], aneurysm
location, the occurrence of rebleeding and delayed cerebral
ischemia, and functional outcome. After centrifugation of
blood samples, the cell pellets were used to extract DNA for
genotyping. The primary outcome was poor functional out-
come, which was defined as a Glasgow Outcome Scale score
of 1–3, 3 months after ictus [26]. Secondary outcome was
clinical deterioration due to delayed cerebral ischemia, for
which we used the definition that was proposed by an inter-
national multidisciplinary research group [3]. The occurrence
of rebleeding was recorded between admission and aneurysm
treatment, and defined as a sudden clinical deterioration with
signs of increased hemorrhage on CT scan compared with
previous CT imaging or found at autopsy, or a sudden clinical
deterioration suspect for rebleeding with fresh blood in the
ventricular drain in which no CT scan or autopsy was obtain-
ed. During collection of clinical data, the investigators were
blinded for the results of genotyping.
Genotyping
The following common allele variants with a frequency of >
5% were investigated: C3 rs1047286, C3 rs2230199, and C5
rs17611. Genotyping was done using TaqMan SNP
Genotyping Assays with the Lightcycler® 480. In case of
unsuccessful genotyping of C5 rs17611, we used data from
a previous genome-wide association study, which partly
included the same patients as in the present study [27]. Due
to the supplementary genome-wide association study data,
genotype success rate for the C5 rs17611 SNP increased from
94.1 to 98.0%. Genotyping was performed on coded DNA
samples, so clinical information remained unknown to the
laboratory personnel.
C5a Levels in Plasma of Genotyped Patients
To determine the relationship between the C5 rs17611 SNP
and C5a levels in plasma, we used plasma samples in a subset
of 229 patients who presented with aneurysmal SAH between
2007 and 2011 (63 males, 176 females, median age 57 years
(range 19–88 years)). Blood samples were obtained in EDTA
tubes between days 1 and 14 after ictus. The samples were
centrifuged and C5a levels in plasma were measured with the
use of Human Complement C5a ELISA Kit (LifeSpan
Biosciences) according to the manufacturers’ instructions.
Serial Measurement of C5a in CSF and Plasma
We performed serial blood withdrawals in 31 patients with
aneurysmal SAH (13 males, 18 females, median age 53 years
(range 32–74 years)) and single measurements in 17 healthy
control patients (6 males, 11 females, median age 53 years
(range 30–63 years)). Blood samples in SAH patients were
obtained in citrate tubes on days 1, 3, 5, 7, 10, 14, and 17 (±
1 day), with day of ictus defined as day 0. The samples were
centrifuged and plasmaC5a levels weremeasuredwith the use
of a C5a EIA kit (Quidel) according to the manufacturers’
Table 1 Patient characteristics
Cohort (N = 930)
Median age (year, interquartile range) 50 (43–59)
Female sex (number, %) 653 (70)
WFNS grading scale on admission (number/total, %)
1
2
3
4
5
481/905 (53)
188/905 (21)
60/905 (7)
115/905 (13)
61/905 (7)
Location of aneurysm in anterior circulation (number/total, %) 802/911 (88)
In-hospital complications (number/total, %)
Rebleeding
Clinical deterioration due to delayed cerebral ischemia
125/914 (14)
174/913 (19)
Glasgow Outcome Scale Score at 3 months (%)
1. Death
2. Vegetative state
3. Severe disability
4. Moderate disability
5. Good recovery
73 (8)
4 (0)
112 (12)
224 (24)
517 (56)
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guidelines (standard curves R2 ranging from 0.9998 to 1, low-
er limit of detection 0.05 ng/mL).
CSF samples were collected from 10 patients with aneu-
rysmal SAH (three males, seven females, median age 57 years
(range 41–75 years)) and three controls in whom CSF was
collected during surgery for an unruptured aneurysm (one
male, two females, ages 49, 60, and 60 years). In 6 patients,
CSF samples were collected from external ventricular drains
and in 4 patients from lumbar drains. CSF was sampled on
days 1, 3, 5, 7, 10, 12, and 14 after SAH with day of ictus
defined as day 0. All CSF samples were immediately centri-
fuged upon collection, and the supernatants were stored at −
80 °C until analysis. C5a levels were measured with the use of
a C5a EIA kit (Quidel) according to the manufacturer’s
guidelines.
SAH Animal Model
To model SAH in mice, we applied the prechiasmatic blood
injection model as described previously, with injection of
60 μL of blood in the prechiasmatic cistern [28, 29]. Body
temperature was maintained at 37 °C. Cerebral blood flow
was measured between 7.5 min prior to and up to 15 min after
blood injection, with a laser Doppler flow meter (BLF22;
Transonics Systems, New York, NY, USA). The success of
SAH creation was confirmed by a sharp reduction in cerebral
blood flow during blood injection. Mean cerebral blood flow
during blood injection dropped to ≤ 25% of baseline in all
groups, which is a reflection of an acute increase in intracra-
nial pressure that is also seen in patients with aneurysmal
SAH. Mice were killed 48 h after blood injection. After intra-
cardiac perfusion-fixation with 4% paraformaldehyde in PBS,
brains were removed and post-fixed for 48 h in 4% parafor-
maldehyde in PBS, pH 7.4. Coronal cuts were made with a
mouse brain matrix (Zivic Instruments, Pittsburgh, PA, USA).
Slices were dehydrated and embedded in paraffin, and cut into
7-μm sections with a microtome.
The following experimental groups were investigated: (a)
wild-type (WT) mice (BALB/c, male, n = 15) with
prechiasmatic injection of 60 μL of blood from a donor WT
mouse (BALB/c, male, n = 15); (b) WT mice (BALB/c, male,
n = 15) with prechiasmatic injection of 60 μL of blood from a
donor WT mouse (BALB/c, male, n = 15) and with a subse-
quent intraperitoneal injection of a neutralizing monoclonal
antibody directed against murine C5 (20 min after creation
of SAH, 1 mg per mouse; clone BB5.1; [30]; and (c)
C5aR−/− mice (C.129S4(B6)-C5ar1tm1Cge/J, 15 times back
crossed to BALB/c, obtained from the Jackson Laboratory,
male, n = 15) with prechiasmatic injection of 60 μL of blood
from a donor C5aR−/− mouse, male, n = 15). All mice were
2 months of age. The experiments were performed in random
order.
Immunocytochemistry
Iba1 and cleaved caspase-3 immunofluorescence imaging was
performed on coronal 7-μm sections that were taken 3 mm
anterior to the cerebellum of the mice. Iba1 (polyclonal rabbit,
1:4000, #019-19741, Wako), cleaved caspase 3 (polyclonal
rabbit, Antibody #9661, 1:100, Cell Signalling), and NeuN
(monoclonal, 1:500,Mab377, Chemicon) were used as prima-
ry antibodies. Hoechst 33258 (1:1000, Sigma-Aldrich) was
used to visualize cell nuclei. We selected four predefined areas
of cerebral cortex to quantify protein expression. Images were
taken with the use of an epifluorescence microscope (× 20
objective, Axio Scope A1, Zeiss) and processed with the use
of Axiovision (Zeiss). We calculated the threshold area per-
centage of Iba1-positive cells with the use of FIJI software
(ImageJ, NIH). The investigators who analyzed Iba1 and
cleaved caspase 3-positive cells were blinded to the experi-
mental group.
Statistical Analysis—Autopsy Study
Optical density values were presented as mean with SEM,
compared between areas of SAH patients and controls, and
analyzed with a Student’s t test for the C1q analysis and a
Mann-Whitney test for the C3/C3b/iC3b analysis.
Statistical Analysis—Genetic Analysis
The number of patients in our cohort (n = 930) was based
on a variant with a minor allele frequency of 0.36 and a
study power of > 80%, to detect an association of the
variant with poor functional outcome with an odds ratio
of ≥ 1.8 (http://pngu.mgh.harvard.edu/~purcell/gpc/). We
calculated whether the genotype frequencies concurred
with the Hardy-Weinberg equilibrium by use of an X2 test
with one degree of freedom with a p value of less than 0.
05 to indicate significance. Differences in genotype fre-
quencies were analyzed with a two-tailed X2 test.
Statistical analyses were performed with SPSS version
20.0 for Windows (IBM, Armonk, NY, USA). We calcu-
lated odds ratios with 95% confidence intervals and per-
formed logistic regression analyses with adjustments for
age, sex, and WFNS grading scale on admission to calcu-
late adjusted odds ratio. C5a levels per genotype of the C5
SNP rs17611 were analyzed by the Kruskal-Wallis test
fo l lowed by Dunn ’s mul t ip le compar i son tes t .
Correlation between plasma C5a levels and functional
outcome 3 months after ictus, measured with the
Glasgow Outcome Scale, was analyzed by partial
Spearman’s rho correlation test and controlled for WFNS
grading scale score on admission.
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Statistical Analysis—Serial C5a Measurements in CSF
and Plasma
Concentrations were presented as mean with SEM. Means of
each serial C5a measurement in plasma were compared with
the mean of the controls, calculated with ANOVA followed by
the Dunnett’s multiple comparisons test. Each serial C5a mea-
surement in CSF was compared with the controls, calculated
with Kruskal-Wallis test, followed by the Dunn’s multiple
comparisons test.
Statistical Analysis—Animal Experiments
The number of mice (n = 15) was based on an assumed mor-
tality rate of 6% (leaving 14 mice available for analysis), a
minimum difference in extent of microglia/macrophage acti-
vation or cells undergoing apoptosis of 25% between groups
with and without C5a ablation, a standard deviation of 20% in
both groups, 5% error, and 80% power.
The results of Iba1 and cleaved caspase-3 immunofluores-
cence stainings were presented as means with SD. Differences
between groupswere calculatedwithKruskal-Wallis test, follow-
ed by theDunn’smultiple comparisons test. Probability values of
< 0.05 were considered to be of statistical significance.
Results
Complement Expression in Brains of SAH Patients
In autopsy brain tissue from SAH patients and controls, we
found a higher expression in SAH patients compared to con-
trols of complement component C1q (control mean ± SEM
0.129 ± 0.007, n = 5, versus SAH mean ± SEM 0.155 ± 0.007,
n = 7; t = 2.66, df = 10; p < 0.05, Fig. 1a and b) and complement
component C3/C3b/iC3b (control mean ± SEM 0.114 ± 0.001
versus SAH mean ± SEM 0.148 ± 0.005; U = 0, p < 0.01, Fig.
1c and d). These results show that C1q and C3/C3b/iC3b im-
munoreactivity is increased in the brain after SAH.
Genetic Association Study of Common Allele Variants
of the Complement C3 and C5 Genes
Inter-individual differences in the inflammatory response
resulting from common polymorphisms in the complement sys-
tem may explain part of the heterogeneity in disease severity
and outcome following aneurysmal SAH. Previously, it was
shown that these polymorphisms are involved in central nervous
system inflammation [31]. We performed a genetic association
study to investigate if common allele variants in C3 and C5
genes are associated with functional outcome and delayed cere-
bral ischemia. Characteristics of the 930 patients included in the
genetic study are shown in Table 1. Poor functional outcome,
measured by the Glasgow Outcome Score 1–3 at 3 months,
occurred in 189 of the 930 patients (20%). Data on genotyping
success rate are shown in Table 2. All genotype frequencies
were in concurrence with the Hardy-Weinberg equilibrium.
The relationship between genotyping and outcome is shown
in Table 3. The C3 SNP frequencies were similar in patients with
poor and good functional outcome, and in patients with and
without delayed cerebral ischemia. The C5 rs17611 allele A
was associated with poor functional outcome (odds ratio 1.49;
95% confidence interval 1.04–2.14; adjusted odds ratio 1.53;
95%CI 1.02–2.28; Table 3), but not with delayed cerebral ische-
mia (odds ratio 1.09; 95% CI 0.78–1.52; adjusted odds ratio
1.10; 95% confidence interval 0.79–1.55; Table 4).
Since the C5 rs17611 allele A was associated with poor
functional outcome, we subsequently measured plasma C5a
levels in 229 genotyped patients with SAH in blood samples
drawn between days 1 and 14 after the hemorrhage. Patients
carrying allele A of the C5 rs17611 SNP had lower plasma
C5a levels (genotype AAmedian 5.3 ng/mL [95% confidence
interval 5.3–7.1 ng/mL]; AG median 13.0 ng/mL [95% con-
fidence interval 13.1–16.0 ng/mL]; GG median 19.3 ng/mL
[95% confidence interval 18.2–25.9 ng/mL]; H = 117.9,
p < 0.0001, Fig. 2a). No correlation was found between plas-
ma C5a levels and poor functional outcome, measured by the
Glasgow Outcome Scale, 3 months after subarachnoid hem-
orrhage (partial Spearman’s rho correlation − 0.09, p = 0.16,
controlled for WFNS grading scale on admission).
Serial C5a Measurements in CSF and Plasma
of Subarachnoid Hemorrhage Patients
We investigated the time-course of plasma C5a levels in 31 pa-
tients with aneurysmal SAH. Blood samples were taken at days
1, 3, 5, 7, 10, 14, and 17 (± 1 day) after aneurysmal SAH. Plasma
C5a levels steadily increased with a peak on day 5 after SAH
(control mean ± SEM7.8 ± 0.9 ng/mL; SAH day 5mean ± SEM
17.9 ± 2.0 ng/mL, F = 3.305, p < 0.01) and dropped thereafter
(Fig. 2b). Furthermore, we used serial CSF samples from 10
patients with aneurysmal SAH up to day 14 after ictus and single
CSF samples from 3 controls with unruptured aneurysms. The
CSF levels of C5a were > 1400 times increased 1 day after an-
eurysmal SAH (control mean ± SEM 0.05 ± 0.03 ng/mL; SAH
day 1 mean ± SEM 71.9 ± 26.4 ng/mL, H = 23.21, p < 0.001)
and slowly decreased over time (Fig. 2c). These data show that
complement activation is strongly increased in the acute phase of
SAH, in particular in the central nervous system.
Functional Analysis of the Role of C5 and C5a in an
SAH Mouse Model
To investigate if C5 contributes to brain injury after SAH and
to study the effect of C5-specific antibodies on the extent of
brain injury, we used 3 groups of mice in which SAH was
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created with the prechiasmatic blood injection model [29]. We
assessed microglia/macrophage activation and cell death 48 h
after SAH induction. We found that Iba1 expression, a
microglia/macrophage marker, was reduced in the C5aR−/−
mice compared to wild-type controls. Moreover, the mice
treated with C5 specific antibody showed similar reduction
in Iba1 expression (C5aR−/− mean ± SD 6.3 ± 0.9%; control
BALB/c mean ± SD 10.8 ± 2.1%; C5 antibody treated mice
mean ± SD 6.7 ± 1.0%; Kruskal-Wallis, Dunn’s post hoc,H =
22.9, p ≤ 0.001; Fig. 3a; quantified in Fig. 3c), indicating a
reduced activation of microglia/macrophages, the innate im-
mune cells of the brain. No difference in Iba1 expression be-
tween the C5aR−/− and C5 antibody treated wildtypemice was
found, showing the potency of this treatment. Furthermore,
the density of cells positive for cleaved caspase 3, marker
for cells undergoing apoptosis, was reduced to a similar de-
gree in the C5aR−/− mice and mice treated with C5 antibody
compared to wild-type controls (C5aR−/−mean ± SD 28 ± 24;
C5 antibody treated BALB/c mean ± SD 26 ± 16; control
BALB/c mean ± SD 47 ± 22; Kruskal-Wallis, Dunn’s post
hoc, H = 8.6, p ≤ 0.05; Fig. 3b; quantified in Fig. 3d), indicat-
ing a reduction in the number of cells undergoing apoptosis.
The majority of cleaved caspase 3-positive cells were also
positive for NeuN, a neuronal marker (Fig. 3b).
Discussion
Weare the first to show in amultilevel approach that complement
factor C5 contributes to brain injury after SAH. We showed that
the complement system is activated in the brain following SAH,
as reflected by the increased immunoreactivity for C1q and C3/
C3b/iC3b in brain tissue of patients who died after SAH com-
pared with brain tissue of patients who died from non-
neurological causes. C5 rs17611 SNP correlated with functional
outcome after SAH and with plasma C5a levels, and that C5a
Fig. 1 Complement expression in human autopsy brain sections. a
Representative images of immunohistochemical staining of C1q on
autopsy brain sections of a control patient, and a subarachnoid
hemorrhage patient. bAverage optical density measurements of C1q. c
Representative images of immunohistochemical staining of C3/C3b/iC3b
on autopsy brain sections of a control patient, and a subarachnoid
hemorrhage patient. d Average optical density measurements of C3/
C3b/iC3b. Scale bar: 100 μm, Student’s t test; *p ≤ 0.05; **p ≤ 0.01;
mean ± SEM
Table 2 Allele frequency, Hardy-Weinberg equilibrium, and genotyping success rate of common complement component polymorphisms in 930
patients with aneurysmal subarachnoid hemorrhage
Gene SNP ID A % B % AA AB BB HWE p value Success rate
C3 rs1047286 80.1% 19.9% 545 267 35 p = 0.750 91%
C3 rs2230199 77.6% 22.4% 590 277 37 p = 0.534 97%
C5 rs17611 43.7% 56.3% 182 432 297 p = 0.274 98%
HWE Hardy-Weinberg equilibrium, SNP single nucleotide polymorphism
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levels in CSF were markedly increased on day 1 after ictus and
gradually decreased within the next 2 weeks. Plasma C5a levels
were increased at a later stage, with a peak concentration around
days 3–10 after ictus. In a mouse model of SAH, mice lacking
C5a receptor had a ≈ 40% reduction of brain injury as reflected
by reduced microglia/macrophage activation and cell apoptosis.
This indicates that C5a is involved in the pathogenesis of brain
injury after experimental SAH. Similarly, mice treated with C5
neutralizing antibodies directly after the hemorrhage had reduced
brain injury. As the mice were treated short after the induction of
SAH and sacrificed 2 days after SAH, this suggests that the
inhibition of C5 has a long-lasting effect. These data indicate that
C5 antibodies may be a promising new treatment option to de-
crease brain injury. Importantly, C5 antibodies are already used
for other clinical indications [32–34]. Furthermore, studies
showed that C5 antibodies are a promising new treatment option
for patients with other neurological diseases, such as pneumo-
coccal meningitis, neuromyelitis optica, and myasthenia gravis
[31, 35, 36].
The C5 rs17611 SNP correlated with poor functional out-
come. This SNP has also been linked to poor outcome after
pneumococcal meningitis [31], adverse cardiovascular out-
comes [37], and periodontitis [38]. Recently, the functional
basis for these disease associations was clarified [39]. Allele
G of the C5 rs17611 SNP causes a missense mutation in the C5
gene, increases the rate of proteolytic activation of C5 and C5a
generation. As a result, patients carrying allele G have in-
creased C5a plasma levels [39]. This is in accordance with
the results from our study, in which we found that patients
carrying allele G of the C5 rs17611 SNP had higher plasma
C5a levels than patients with allele A. Although patients with
allele A had lower plasma C5a levels and were at increased risk
of poor functional outcome, the plasma levels were not corre-
lated with poor functional outcome. Since complement activa-
tion was much stronger upregulated in the CSF than in plasma,
it remains to be investigated if C5a levels in CSF correlate
better with functional outcome than C5a levels in plasma.
There are a number of mechanisms by which complement
activation can contribute to brain injury. The complement system
has been linked to the regulation of synapse numbers [40]. In
particular, complement components C1q and C3 have been im-
plicated to facilitate the removal of synapses [41]. Unwanted
synapses are tagged with C1q and C3, thereby becoming eligible
for elimination. Microglia recognize these components and start
to remove the synapse [42]. Synaptic pruning by microglia oc-
curs during development, but also in diseases such as glaucoma
and Alzheimer’s disease and after viral infection [41, 43, 44].
Therefore, complement activation in response to SAH may also
induce excessive synapse pruning. However, while early com-
plement components are involved in synapse elimination, the
involvement of downstream components, such as C5 and C5a,
remain to be investigated. Another mechanism by which com-
plement activation may contribute to brain injury is by the mem-
brane attack complex, formed byC5b-C9 complexes. Hemolysis
of blood in the CSF is thought to be complement system medi-
ated by activation of the membrane attack complex [45, 46]. The
Table 3 Genotyping analysis of common complement component polymorphisms in 741 patients with favorable outcome and 189 patients with
unfavorable outcome
Gene Allele SNP ID Favorable outcome Unfavorable outcome OR (95%CI) aOR (95%CI)
AA AB BB AA AB BB
C3 C/T rs1047286 422 220 27 123 47 8 1.31 (0.92–1.87) 1.46 (0.98–2.17)
C3 C/G rs2230199 462 227 28 128 50 9 0.84 (0.59–1.18) 0.75 (0.51–1.11)
C5 A/G rs17611 144 333 249 38 99 48 1.49 (1.04–2.14) 1.53 (1.02–2.28)
Allele in bold is used for analysis
aOR adjusted odds ratio (adjusted for gender, age at time of ictus, and WFNS grading scale on admission), CI confidence interval, OR odds ratio, SNP
single nucleotide polymorphism
Table 4 Genotyping analysis of common complement component polymorphisms in 725 patients without DCI and 169 patients with DCI
Gene Allele SNP ID No DCI DCI OR (95%CI) aOR (95%CI)
AA AB BB AA AB BB
C3 C/T rs1047286 432 214 28 103 47 7 0.93 (0.67–1.30) 0.95 (0.67–1.33)
C3 C/G rs223019 467 222 29 113 49 7 1.11 (0.80–1.53) 1.10 (0.79–1.53)
C5 A/G rs17611 152 334 239 27 91 51 1.09 (0.78–1.52) 1.10 (0.79–1.55)
Allele in bold is used for analysis
aOR adjusted odds ratio (adjusted for gender, age at time of ictus, andWFNS grading scale on admission), CI confidence interval,DCI delayed cerebral
ischemia, OR odds ratio, SNP single nucleotide polymorphism
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membrane attack complexmay also bind bystander cells, such as
endothelial cells, ependymal cells and other brain cells, and there-
by induce brain injury.
To address the specific involvement of C5 and C5a in brain
injury after SAH, we used C5aR−/− and wild-type mice treat-
ed with neutralizing antibody against C5. While the antibody
treatment inhibits the generation of both activation products of
C5, namely C5a and C5b, only the C5aR-mediated functions
of C5a are absent in the C5aR−/−mice. Our experimental data
show that apoptosis and microglia activation are reduced in
mice lacking C5aR as well as mice treated with a single dose
of neutralizing antibody against C5. These findings provide
evidence for the detrimental role of C5a in brain injury after
SAH and are in line with previous studies in which C5aR
deficiency as well as treatment with a C5aR antagonist result-
ed in reduced apoptosis, increased cell viability, and reduced
infarct volume after ischemic stroke [47, 48]. As C5a pro-
motes neuronal apoptosis by acting directly through neuronal
C5aR in-vitro [48], it is conceivable that the same neuronal
mechanism is involved in brain injury after SAH.
C5aR is also expressed by microglia which upregulate
C5aR in response to injury [49–51]. Thus, the reduced activa-
tion of microglia in the C5aR−/− and anti-C5 antibody treated
mice may not only be an indirect effect of reduced cell death
but may also be explained by direct effects of the intervention
on these cells. In experimental spinal cord injury, C5aR sig-
naling in the acute phase has been shown to contribute to
tissue damage through local proinflammatory cytokine pro-
duction and the recruitment of inflammatory monocytes/
macrophages [52]. As Iba1 is expressed in microglia as well
as in blood born monocytes/macrophages, it is possible that
recruited inflammatory cells together with activated microglia
play a role in SAH-induced brain injury.
The effects of C5a in the context of brain tissue injury may
not be solely detrimental. C5a has been shown to be neuro-
protective during neuronal maturation [53] and to protect neu-
rons against glutamate-mediated toxicity [54]. Through the
upregulation of microglial glutamate receptor GLT-1, C5a
can also increase the capacity of microglia to clear excessive
glutamate [55]. In addition, in the postacute stage after spinal
cord injury, signaling through the C5a-C5aR axis appears to
serve a protective and/or reparative role [52]. Thus, in light of
the potential beneficial effects of C5a, the timing of the ther-
apeutic intervention targeting C5aR after SAHmay need to be
carefully determined.
Interestingly, C5a can bind to Gpr77, also termed C5a-like
receptor 2 (C5L2; [56]). The function of C5L2 is controversial,
as both pro- and anti-inflammatory properties of this receptor
have been described [56]. Our results that C5aR deficiency and
inhibition of C5 activation reduced brain injury to the same ex-
tent support the contention that the deleterious effects of C5a in
the acute phase after SAH are mediated mainly by its canonical
receptor C5aR. In addition to the release of C5a, the proteolytic
Fig. 2 C5a levels measured in plasma and CSF of aneurysmal subarachnoid
hemorrhage patients. a Plasma C5a levels (ng/mL) of genotyped patients,
grouped per genotype of the C5 single nucleotide polymorphism rs17611;
blood samples were obtained between day 1 and day 14 postsubarachnoid
hemorrhage; AA; n = 53, AG; n = 98, GG; n = 78; Kruskal-Wallis, Dunn’s
multiple comparison, ***p ≤ 0.001, median ± 5–95 percentile.bSequentially
measured C5a levels in plasma of aneurysmal subarachnoid hemorrhage
patients (n = 31), versus plasma C5a levels of healthy controls (n = 17).
Blood samples were taken on days 1, 3, 5, 7, 10, 14, and 17 (± 1 day) after
subarachnoid hemorrhage. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ANOVA,
Dunnett’s post hoc; mean ± SEM. c Sequentially measured C5a levels in
CSF of aneurysmal subarachnoid hemorrhage patients (n = 10) versus CSF
C5a levels of patients with an unruptured aneurysm (n = 3). CSF obtained on
days 1, 3, 5, 7, 10, 12, and 14 after subarachnoid hemorrhage. *p ≤ 0.05,
**p ≤ 0.01, Kruskal-Wallis test, Dunn’s post hoc; mean ± SEM
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activation of C5 triggers the formation of the membrane attack
complex, C5b-9, leading to neuronal death through apoptosis
[57] or cell lysis [55]. However, in light of our findings of the
comparable effect of C5aRdeficiency and anti-C5 antibody treat-
ment, a substantial contribution of C5b-9 to brain injury after
SAH appears unlikely.
There are potential limitations to our study. The human brain
tissue used in the autopsy study was from deceased patients. The
increased expression of complement C1q and C3/C3b/iC3b may
not reflect the situation of patients with a more favorable out-
come. However, the CSF used to measure C5 levels was of
patients of both favorable and unfavorable outcomes, and
Fig. 3 C5 antibody treatment reduces brain injury in experimental
subarachnoid hemorrhage. a Representative images of mouse cortex
stained with antibody against Iba-1 (orange); cell nuclei in blue
(Hoechst). bRepresentative images of mouse cortex stained with anti-
body against cleaved caspase 3 (CC3; green); NeuN (red) and cell nuclei
in blue (Hoechst). c C5a receptor deficient (C5aR−/−) and wild-type mice
treated with C5-specific antibodies had a > 38% reduction in microglia/
macrophage activation compared to untreated wild-type mice. Kruskal-
Wallis, Dunn’s post hoc. d C5aR−/− mice and control BALB/c mice
treated with C5-specific monoclonal antibodies had > 39% reduction in
cells undergoing apoptosis, compared to untreated wild-type mice 48 h
after subarachnoid hemorrhage. Kruskal-Wallis, Dunn’s post hoc; n = 15
mice per group; ****p ≤ 0.0001, ***p ≤ 0.001, *p ≤ 0.05; mean ± SD;
scale bars 30 μm.
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showed a sharp increase in complement C5 levels after SAH.
This suggests activation of the complement cascade both in good
and poor grade SAH.
In conclusion, the present study highlights the role of C5a
in the development of brain injury after SAH and identifies C5
antibodies as a potential novel treatment strategy to reduce
brain injury after SAH.
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